Vectura Group Initiates Legal Proceedings Against GSK
July 27 2016 - 1:16PM
Dow Jones News
LONDON--Vectura Group PLC (VEC.LN) said on Wednesday it has
filed a patent infringement lawsuit against GlaxoSmithKline PLC
(GSK.LN) because GSK didn't exercise the option to license any
additional patents under an agreement with Vectura dated August
2010.
Vectura, which specialises in products for inhaled airways
disease, also reiterated its 2016 revenue guidance.
The lawsuit claims infringement of one of Vectura's patents in
the U.S., the company said. The separate agreement with GSK
relating to the legacy Skyepharma dry powder formulation technology
used in GSK's Ellipta product range is unaffected by this lawsuit,
Vectura said.
In August of 2010, GSK and Vectura entered a license and
option-to-licence agreement relating to a number of Vectura patent
families and various formulation technologies relevant to the
Ellipta products.
Vectura shares at 1630 GMT up 0.20 pence, or 0.1%, at 150 pence,
while GSK shares up 29.50 pence, or 1.8%, at 1,696.50 pence.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
July 27, 2016 13:01 ET (17:01 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024